Niklason Laura E 4
4 · Humacyte, Inc. · Filed Nov 17, 2025
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Niklason Laura E
DirectorPresident, CEO and Director
Transactions
- Award
Stock Options (right to buy)
2025-11-16+311,100→ 311,100 totalExercise: $1.23Exp: 2035-11-16→ Common Stock (311,100 underlying)
Footnotes (1)
- [F1]The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027.